The rich history of Dyadic represents a microcosm of how modern biotechnology is revolutionizing science, medicine, agriculture, and engineering to improve how we feed, fuel, and heal the world.
Going forward we intend to focus on on the pharmaceutical industry which we have long believed is one of the most attractive opportunities in which to apply the C1 technology. We believe that the C1 technology platform has the potential to be a safe and efficient expression system to help pharmaceutical and biotech companies speed up the development and lower the cost of manufacturing biologic vaccines and drugs to bring more affordable treatments to a greater number of patients, while helping to ease the burden biologic drugs are having on patients and the global healthcare systems, but most importantly saving lives.
Going forward we intend to focus on on the pharmaceutical industry which we have long believed is one of the most attractive opportunities in which to apply the C1 technology. We believe that the C1 technology platform has the potential to be a safe and efficient expression system to help pharmaceutical and biotech companies speed up the development and lower the cost of manufacturing biologic vaccines and drugs to bring more affordable treatments to a greater number of patients, while helping to ease the burden biologic drugs are having on patients and the global healthcare systems, but most importantly saving lives.
Location: United States, Florida, Jupiter Island
Employees: 11-50
Phone: +1 561-743-8333
Founded date: 1979
Investors 1
| Date | Name | Website |
| - | Montrose C... | montroseca... |
Mentions in press and media 21
| Date | Title | Description |
| 09.10.2025 | Animal-Free Protein & Enzyme Producer Dyadic Applied BioSolutions to Receive Milestone Payments Following Commercial Progress | Global biotechnology company Dyadic Applied BioSolutions has announced the achievement of additional milestone payments in its collaborations with Proliant Health & Biologicals and Inzymes ApS. The company, which produces precision-engi... |
| 08.08.2023 | Dyadic’s Revolutionary Animal-Free Bovine Serum Albumin to Solve Costs and Ethical Challenges of Cultivated Meat and Pharmaceuticals | Biotechnology company Dyadic International, Inc. (NASDAQ: DYAI) announces that independent analysis has confirmed that its revolutionary animal-free bovine serum albumin is structurally identical to commercial animal albumin, opening new co... |
| 08.06.2023 | The Week in AgriFoodTech: Green Coffee Co brews up $25m, ChatGPT designs robotic harvesting, Zume shuts down | Despite a general scarcity of agrifoodtech funding this week, a few companies announced notable rounds, including the Green Coffee Company, which will expand across Colombia, and Turkish food waste management startup Fazla. Elsewhere, ChatG... |
| 08.03.2022 | IWD 2022: Celebrating the Queens Of Alt Protein Who Are Forging The Future Of Food | 166 1 167 Shares 16 Mins Read The two biggest plant-based protein startups in the world are run by men. The majority of the rising cell-based protein startups are also run by men, alongside most of the vegan investment groups that fund them... |
| 10.02.2022 | Dyadic International : and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine - Form 8-K | Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine ● The exclusive license agreement between Dyadic and Phibro utilizes Dyadic engineered C1-cells to produce specific targ... |
| 07.01.2022 | Dyadic International : Investor Presentation January 2022 | Revolutionary C1 Protein Production Platform Addressing Today'sVaccine & Therapeutic Shortfalls Through the Science of Tomorrow… January 2022 M A K I N G H E A L T H C A R E A C C E S S I B L E & A F F O R D A B L E G L O B A L L Y ... |
| 17.12.2021 | Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform | JUPITER, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary... |
| 17.12.2021 | Dyadic International : Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform - Form 8-K | Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform JUPITER, FL / December 17, 2021, Dyadic International, Inc. ("Dyadic", "w... |
| 11.11.2021 | Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress - Form 8-K | Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress ● COVID-19 vaccine candidate, DYAI-100, continues to advance towards first-in-human clinical trial to validate C1 produced proteins are safe in human... |
| 09.11.2021 | Dyadic Appoints Chief Business Officer to Executive Leadership Team - Form 8-K | Dyadic Appoints Chief Business Officer to Executive Leadership Team JUPITER, FL / November 9, 2021 Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), ... |
Show more